Company Filing History:
2 out of 441 
2 out of 14 Years Active: 2019-2022
Title: Suguru Ueno: Innovator in Antitumor Drug Development
Introduction
Suguru Ueno is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of antitumor drug development, holding a total of 2 patents. His work focuses on creating effective therapies that enhance patient safety and treatment outcomes.
Latest Patents
Ueno's latest patents include an innovative anti-HER3 antibody-drug conjugate. This invention aims to provide an antitumor drug with excellent therapeutic effects, ensuring both efficacy and safety. The antibody-drug conjugate is designed such that an antitumor compound is conjugated to an anti-HER3 antibody via a specific linker structure. This structure allows for the effective targeting of cancer cells, enhancing the overall treatment potential.
Career Highlights
Throughout his career, Suguru Ueno has worked with notable companies, including Daiichi Sankyo Company, Limited and Daiichi Sankyo Europe GmbH. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Ueno has collaborated with esteemed colleagues such as Thore Hettmann and Reimar Abraham. These partnerships have further enriched his research and development efforts in the pharmaceutical industry.
Conclusion
Suguru Ueno's contributions to antitumor drug development highlight his commitment to improving cancer treatment. His innovative approaches and collaborations continue to pave the way for advancements in medical therapies.